Belayneh Mekuriaw, Tegegne Bantayehu Addis, Lemma Mulualem, Abay Zenahebezu, Belyhun Yeshambel
Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Debremarkos University, Debre Markos, Ethiopia.
Department of Pharmacy, College of Medicine and Health Sciences, Debremarkos University, Debre Markos, Ethiopia.
Front Immunol. 2025 Jun 18;16:1553411. doi: 10.3389/fimmu.2025.1553411. eCollection 2025.
Hepatitis B virus (HBV) is a major global public health issue and the most common etiology of chronic liver disease (CLD). The relationship between and HBsAg+ patients was not well investigated and has attracted much scientific and clinical interest, although the relationship remains controversial.
This study aimed to assess the clinical and biochemical characteristics of HBsAg+ liver disease patients with and without infection.
From April 1, 2021, to March 30, 2022, a hospital-based cross-sectional study was done at the University of Gondar Comprehensive Specialized Hospital on 384 known HBsAg+ liver disease patients recruited using a convenient sampling technique. All the HBsAg+ patients were tested for fecal antigen, and blood specimens were analyzed for ALT, AST, ALP, ALB, TP, BILT, TG, and TChol tests using an automated biochemistry analyzer. GraphPad Prism 8.02 and SPSS 25 were used for data analysis, considering a statistically significant of 0.05.
co-infection was found in 153 (39.8%) of HBsAg+ study participants. ALT, AST, and total cholesterol mean levels were significantly higher in patients co-infected with (p<0.04). Portal hypertension (47.8%), variceal bleeding (60.7%), and hepatocellular carcinoma (HCC) (57.5%) were more common (p< 0.01) in patients with HBV and H. pylori co-infection.
ALT, AST, and TChol mean levels were higher in co-infected HBsAg+ patients. Our findings showed that has a role in the elevation of clinical and biochemical parameters in HBsAg+ liver diseases.
乙型肝炎病毒(HBV)是一个重大的全球公共卫生问题,也是慢性肝病(CLD)最常见的病因。尽管二者关系仍存在争议,但关于[此处原文缺失某内容]与HBsAg阳性患者之间的关系尚未得到充分研究,且已引起了诸多科学和临床关注。
本研究旨在评估合并或未合并[此处原文缺失某内容]感染的HBsAg阳性肝病患者的临床和生化特征。
2021年4月1日至2022年3月30日,在贡德尔大学综合专科医院开展了一项基于医院的横断面研究,对384例已知的HBsAg阳性肝病患者采用便利抽样技术进行招募。所有HBsAg阳性患者均检测粪便[此处原文缺失某内容]抗原,并使用自动生化分析仪对血液标本进行谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、白蛋白(ALB)、总蛋白(TP)、总胆红素(BILT)、甘油三酯(TG)和总胆固醇(TChol)检测。采用GraphPad Prism 8.02和SPSS 25进行数据分析,将具有统计学意义的P值设定为0.05。
在153例(39.8%)HBsAg阳性研究参与者中发现了[此处原文缺失某内容]合并感染。合并[此处原文缺失某内容]感染患者的ALT、AST和总胆固醇平均水平显著更高(P<0.04)。在HBV和幽门螺杆菌合并感染的患者中,门静脉高压(47.8%)、静脉曲张出血(60.7%)和肝细胞癌(HCC)(57.5%)更为常见(P<0.01)。
合并[此处原文缺失某内容]感染的HBsAg阳性患者的ALT、AST和TChol平均水平更高。我们的研究结果表明,[此处原文缺失某内容]在HBsAg阳性肝病的临床和生化参数升高方面起作用。